Trial · NCT01446809
Results by group24
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 24
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change in Maximum SUV of Tumors Measured by FDG-PET Pre- and Post Receipt of Pazopanib Versus Placebo | Pazopanib | -0.1 | Full Range -14.7 to 3.5 | Standardized uptake value-SUV | |
| Change in Maximum SUV of Tumors Measured by FDG-PET Pre- and Post Receipt of Pazopanib Versus Placebo | Placebo | -0.1 | Full Range -2.2 to 6.0 | Standardized uptake value-SUV | |
| Change in Maximum SUV of Tumors Measured by FDG-PET Post Receipt of 2 Courses of Preoperative Chemotherapy | Pazopanib | -1.1 | Full Range -32.7 to 5.0 | SUV | |
| Change in Maximum SUV of Tumors Measured by FDG-PET Post Receipt of 2 Courses of Preoperative Chemotherapy | Placebo | -4.0 | Full Range -11.2 to -0.3 | SUV | |
| Tumor Response by RECIST Criteria | Pazopanib | Stable Disease | 14 | Participants | |
| Tumor Response by RECIST Criteria | Placebo | Stable Disease | 6 | Participants | |
| Tumor Response by RECIST Criteria | Pazopanib | Progressive Disease | 0 | Participants | |
| Tumor Response by RECIST Criteria | Placebo | Progressive Disease | 1 | Participants | |
| Tumor Response by RECIST Criteria | Pazopanib | Stable Disease | 11 | Participants | |
| Tumor Response by RECIST Criteria | Placebo | Stable Disease | 5 | Participants | |
| Tumor Response by RECIST Criteria | Pazopanib | Progressive Disease | 2 | Participants | |
| Tumor Response by RECIST Criteria | Placebo | Progressive Disease | 0 | Participants | |
| Tumor Response by RECIST Criteria | Pazopanib | Partial Response | 1 | Participants | |
| Tumor Response by RECIST Criteria | Placebo | Partial Response | 1 | Participants | |
| Pharmacokinetic Profile of Pazopanib | Pazopanib | 56.38 | Standard Deviation 0.94 | ng/mL | |
| Pharmacokinetic Profile of Pazopanib | Placebo | 0 | Standard Deviation 0 | ng/mL | |
| Change in Levels of VEGF and Soluble VEGFR2 Assessed by ELISA on Plasma and Tumor Extracts | Pazopanib | NA | percentage of concentration | ||
| Change in Levels of VEGF and Soluble VEGFR2 Assessed by ELISA on Plasma and Tumor Extracts | Placebo | NA | percentage of concentration | ||
| Overall Survival | Pazopanib | 12 | Participants | ||
| Overall Survival | Placebo | 4 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01446809/results